EBS Q2 2019 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$243M+10.4% YoY

Gross Profit

$79M32.3% margin

Operating Income

-$7M-2.9% margin

Net Income

-$10M-3.9% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+27.6%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$50M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.3B

Stockholders' Equity

$989M

Cash & Equivalents

$177M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$243M	$220M	+10.4%
Gross Profit	$79M	$110M	-28.8%
Operating Income	-$7M	$67M	-110.5%
Net Income	-$10M	$50M	-119.0%

Revenue Segments

Product

$184M75%

Contracts and Grants

$41M17%

Contract Development And Manufacturing

$19M8%

Geographic Segments

UNITED STATES

$133M55%

Non-US

$110M45%